Study suggests tumour microenvironments could predict cancer progression
NSCLC is the most common type of lung cancer and is responsible for up to 85% of all cases
Read More
Tag: Bristol Myers Squibb
Cancer treatment could identify patients most likely to respond to cancer drugs
Tumours with high mtDNA mutations more likely to respond to Opdivo
Read More
- KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy
- Pepaxti study supports use in wider myeloma population
- UCB reports positive outcomes for bimekizumab in psoriatic arthritis
- AstraZeneca wins US approval for first‑in‑class Baxfendy in hypertension
- Cellbxhealth partners with AdventHealth on CTC‑based monitoring in two major cancer studies
